antiretrovirals

Bioavailability of Coformulated ART Dispersible Tablet Comparable to Standard Formulation

Bioavailability of Coformulated ART Dispersible Tablet Comparable to Standard Formulation

By

A dispersible fixed-dose combination tablet formulation of abacavir/dolutegravir/lamivudine for the treatment of HIV-1 had higher bioavailability of dolutegravir compared to the nondispersible film-coated tablet.

Common Antiretrovirals Have Same Likelihood of Certain Disorders After Initiation

Common Antiretrovirals Have Same Likelihood of Certain Disorders After Initiation

By

Incidence of body fat redistribution/accumulation, pancreatic disorders, musculoskeletal disorders, IRIS, severe systemic rash, and HSR did not differ among common prescribed antiretrovirals.

In Utero Antiretroviral Exposure Associated With Higher Neurological Risk

In Utero Antiretroviral Exposure Associated With Higher Neurological Risk

By

Children who are HIV-exposed, but uninfected, demonstrated a higher risk of adverse neurologic events during infancy and early childhood associated with ART exposure in-utero.

Integrated Intervention Engages PLWHIV who Inject Drugs

Integrated Intervention Engages PLWHIV who Inject Drugs

By

A flexible, scalable intervention increases antiretroviral therapy and medication-assisted treatment use while reducing mortality in people who inject drugs.

Cryptococcal Meningitis May Be Linked With Higher Mortality in PLWHIV

Cryptococcal Meningitis May Be Linked With Higher Mortality in PLWHIV

By

Antiretroviral therapy initiation within 4 weeks of a cryptococcal meningitis diagnosis in PLWHIV appears to be associated with a higher mortality risk.

Certain Patient Characteristics May Augment Tenofovir in Viral Suppression of HIV

Certain Patient Characteristics May Augment Tenofovir in Viral Suppression of HIV

Tenofovir diphosphate in dried blood spots was strongly associated with virologic suppression in those living with HIV on TDF-based therapies.

FDA Updates Labeling for Several HIV Medications to Include Interaction Data With DOACs

FDA Updates Labeling for Several HIV Medications to Include Interaction Data With DOACs

By

The FDA has approved labeling updates for Genvoya, Stribild and Tybost to include new drug-drug interaction data.

International Antiviral Society-USA Updates Recommendations for HIV Treatment and Prevention

International Antiviral Society-USA Updates Recommendations for HIV Treatment and Prevention

By

The International Antiviral Society-USA Panel has updated its recommendations for the management and prevention of HIV infection, to reflect the most current data on new treatment regimens and strategies.

Protease Inhibitors May Worsen Outcomes for Patients With HIV, Heart Failure

Protease Inhibitors May Worsen Outcomes for Patients With HIV, Heart Failure

Ritonavir-boosted protease inhibitor therapy is associated with worse outcomes, including death, in patients with HIV and heart failure.

Guidelines for ART Updated for Those With or at Risk for HIV

Guidelines for ART Updated for Those With or at Risk for HIV

ART recommended for almost all HIV-infected; should be initiated as soon as possible post diagnosis.

Juluca Maintains Viral Suppression in HIV Patients Through 100 Weeks

Juluca Maintains Viral Suppression in HIV Patients Through 100 Weeks

By

The SWORD 1 and SWORD 2 trials enrolled 1027 HIV-infected and virologically suppressed adults; both trials had an early (Day 1 to Week 52) and late (Week 52 to Week 148) switch phase.

Fixed-Dose Bictegravir Regimen: A Safe Alternative in Adults With HIV-1

Fixed-Dose Bictegravir Regimen: A Safe Alternative in Adults With HIV-1

By

Fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide might be a safe and efficacious alternative to continued boosted protease inhibitor therapy in patients with HIV-1

Fixed-Dose Bictegravir, Emtricitabine, Tenofovir Alafenamide Is Efficacious HIV-1 Treatment Option

Fixed-Dose Bictegravir, Emtricitabine, Tenofovir Alafenamide Is Efficacious HIV-1 Treatment Option

By

The fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide might provide a safe and efficacious option for ongoing treatment of HIV-1 infection

Switch to Dolutegravir Regimen Improves Lipid Profile in HIV+ Patients

Switch to Dolutegravir Regimen Improves Lipid Profile in HIV+ Patients

By

Immediate and deferred switching from a boosted protease inhibitor to a dolutegravir regimen in HIV + patients is found to be highly efficacious.

Generic HIV Medicines: Boon or Bust?

Generic HIV Medicines: Boon or Bust?

By

Generic antiretroviral agents have had a dramatic effect on outcomes in developing nations, and their availability in developed countries is rapidly expanding as more brand-name drugs are coming off patent. But unique challenges surrounding their use remain.

Single-Tablet HIV Regimen Improves Retention in Care and Virologic Suppression

Single-Tablet HIV Regimen Improves Retention in Care and Virologic Suppression

By

Investigators assessed adherence to antiretroviral therapy, retention in care, and virologic outcomes in patients receiving once-daily single-tablet and multiple-tablet antiretroviral therapy regimens.

Emerging Technologies to Manage Antiretroviral Therapy Adherence

Emerging Technologies to Manage Antiretroviral Therapy Adherence

By

The rapidly developing landscape of antiretroviral therapy adherence monitoring has great potential for clinical application, but cost-effectiveness and feasibility studies are needed to define the appropriate roles for these new technologies.

Worse Cognitive Outcomes Associated With CMV Antibodies Following ART for HIV

Worse Cognitive Outcomes Associated With CMV Antibodies Following ART for HIV

By

Investigators sought to determine the association between antiretroviral therapy and cytomegalovirus infection in individuals with HIV, as well as the potential impact of both on neurocognitive performance.

Increased Risk for Abdominal Obesity Found in People Living With HIV

Increased Risk for Abdominal Obesity Found in People Living With HIV

By

The Copenhagen Co-morbidity in HIV Infection (COCOMO) study assessed the association between risk factors for cardiovascular disease and HIV infection.

Rising Incidence of Diabetes in Adults With HIV on Antiretroviral Therapy

Rising Incidence of Diabetes in Adults With HIV on Antiretroviral Therapy

By

More research is needed to better capture the interplay between prediabetes/diabetes and antiretroviral therapy in people with HIV.

Alcohol Use in HIV Not Associated With Short-Term CD4 Cell Count Decline

Alcohol Use in HIV Not Associated With Short-Term CD4 Cell Count Decline

By

Unhealthy alcohol use does not appear to have a short-term direct biological effect on CD4 cell count.

Prognostic Value of Plasma JC Virus-DNA in Progressive Multifocal Leukoencephalopathy

Prognostic Value of Plasma JC Virus-DNA in Progressive Multifocal Leukoencephalopathy

Polyomavirus JC-DNA assessment in plasma samples might complement progressive multifocal leukoencephalopathy diagnosis, especially when cerebrospinal fluid (CSF) is unavailable or polyomavirus JC-DNA is not detectable in CSF.

Mortality in HIV-Infected Children Predicted by Urine TB Lipoarabinomannan

Mortality in HIV-Infected Children Predicted by Urine TB Lipoarabinomannan

Benefits of urine lipoarabinomannan include its rapid point-of-care platform, low cost, and readily accessible sample type.

HIV Care Continuum: Effects of Depression, Alcohol Use on Early Retention in ART

HIV Care Continuum: Effects of Depression, Alcohol Use on Early Retention in ART

By

Mental health at the time of antiretroviral therapy initiation indicates early effect on the HIV care continuum.

More Evidence That Early Diagnosis of HIV and Early ART Are Beneficial

More Evidence That Early Diagnosis of HIV and Early ART Are Beneficial

By

Since early ART limits HIV reservoir size and preserves central memory CD4 cells, patients treated from primary HIV infection with low HIV-DNA levels might be good candidates for future HIV cure strategies.

Acquired HIV Drug Resistance Unlikely With Immediate ART Initiation

Acquired HIV Drug Resistance Unlikely With Immediate ART Initiation

By

In high-income countries, the need for second-line treatments due to the development of acquired drug resistance will increase only slightly under the new ART initiation guidelines.

Higher CKD Risk in HIV With Combination Tenofovir, Boosted Protease Inhibitor

Higher CKD Risk in HIV With Combination Tenofovir, Boosted Protease Inhibitor

By

In patients living with HIV receiving TDF with a ritonavir-boosted protease inhibitor, the risk of CKD may be increased.

Pausing ART to Identify Biomarkers for HIV RNA Rebound: Safety and Ethical Considerations

Pausing ART to Identify Biomarkers for HIV RNA Rebound: Safety and Ethical Considerations

By

Dr Gianella Weibel talks with Dr Li and Dr Dubé, investigators of a new study from the AIDS Clinical Trials Group, which uses an intensively monitored antiretroviral pause to identify changes in HIV reservoirs after anti-HIV medications are stopped.

No Change in Brain Structure, Cognitive Performance in Aviremic HIV

No Change in Brain Structure, Cognitive Performance in Aviremic HIV

By

Study suggests that early initiation of combination antiretroviral therapy and full viral suppression may preserve long-term brain health.

New ART Recommendations for Pregnant Women With HIV

New ART Recommendations for Pregnant Women With HIV

By

The GRADE framework recommendations provide guidance for combination treatment regimens based on 2 systemic reviews, patient considerations, fetal outcomes, and practical issues.

Sign Up for Free e-newsletters